Skip to main content
Top
Published in: Journal of Inflammation 1/2013

Open Access 01-08-2013 | Poster presentation

Interleukin-6 neutralization alleviates acute exacerbation-like disease in a model of cigarette smoke-induced pulmonary inflammation

Authors: John Kubera, Katherine Hammerman, Cara MM Williams, Cedric Hubeau

Published in: Journal of Inflammation | Special Issue 1/2013

Login to get access

Excerpt

Increased systemic and pulmonary levels of interleukin (IL)-6 have been associated with the severity of acute exacerbations and accelerated decline of lung function in COPD patients. The demonstration that IL-6 plays a pivotal role in AE-related pulmonary symptoms and therefore represents a therapeutic target for the treatment of COPD, remains elusive. We used a murine model where C57BL/6 female mice are exposed to cigarette smoke (CS) twice daily through a nose-only system, while being punctually challenged intranasally with poly I:C, a synthetic ligand for Toll Like Receptor-3 (TLR3). This protocol recapitulates several aspects of pulmonary inflammation as seen in acute exacerbations of COPD, including prominent airway neutrophilia as well as increased levels of type I interferon, GM-CSF, IL-6, KC, MIP-1 alpha, RANTES, and TNF-alpha in bronchoalveolar lavage (BAL) samples. Using this model, IL-6 deficient mice showed a susceptibility to CS-induced pulmonary inflammation that, overall, was comparable to that found with wild-type (WT) control mice. In contrast, using the same model with WT mice treated intraperitoneally with IL-6 neutralizing antibodies (rat IgG1, clone MP5-20F3, 25 mg/kg thrice weekly) diminished blood counts of lymphocytes (p=0.0070) and monocytes (p=0.0091), while this treatment also depleted BAL levels of IL-6 (p=0.0002) and reduced BAL levels of KC (p=0.0220). Total BAL cellularity was found to be largely decreased (p<0.0001) as well as BAL numbers of neutrophils (p=0.0031), lymphocytes (p<0.0001) and macrophages (p<0.0001), while inflammatory infiltrates seemed reduced in lung tissue sections from treated mice. Our results show that the neutralization of IL-6 largely abrogates pulmonary inflammation in CS-exposed mice, and therefore indicate that IL-6 may be a valid therapeutic target for the treatment of COPD, in particular in episodes of acute exacerbation. …
Metadata
Title
Interleukin-6 neutralization alleviates acute exacerbation-like disease in a model of cigarette smoke-induced pulmonary inflammation
Authors
John Kubera
Katherine Hammerman
Cara MM Williams
Cedric Hubeau
Publication date
01-08-2013
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue Special Issue 1/2013
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-10-S1-P33

Other articles of this Special Issue 1/2013

Journal of Inflammation 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.